The Novo Nordisk Foundation, which operates independently from the pharma company, is pumping DKK 1.8 billion ($260 million) to launch an initiative designed to develop respiratory disease vaccines.
The Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) will begin in the first quarter of next year. It will hire up to 200 people internally from the foundation as well as externally.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.